<h4>Background</h4>Current diagnosis of antiphospholipid syndrome (APS) relies on antiphospholipid antibodies (aPL) testing, but false-positive aPL results and asymptomatic aPL carriers pose significant clinical challenges. This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.